370 related articles for article (PubMed ID: 24248060)
1. Neuroprotective effects of psychotropic drugs in Huntington's disease.
Lauterbach EC
Int J Mol Sci; 2013 Nov; 14(11):22558-603. PubMed ID: 24248060
[TBL] [Abstract][Full Text] [Related]
2. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.
Lauterbach EC
Am J Neurodegener Dis; 2016; 5(1):29-51. PubMed ID: 27073741
[TBL] [Abstract][Full Text] [Related]
3. Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.
Lauterbach EC
Neural Regen Res; 2016 Nov; 11(11):1712-1726. PubMed ID: 28123400
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.
Chiu CT; Liu G; Leeds P; Chuang DM
Neuropsychopharmacology; 2011 Nov; 36(12):2406-21. PubMed ID: 21796107
[TBL] [Abstract][Full Text] [Related]
5. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.
Duan W; Peng Q; Masuda N; Ford E; Tryggestad E; Ladenheim B; Zhao M; Cadet JL; Wong J; Ross CA
Neurobiol Dis; 2008 Jun; 30(3):312-322. PubMed ID: 18403212
[TBL] [Abstract][Full Text] [Related]
6. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?
Chuang DM
Crit Rev Neurobiol; 2004; 16(1-2):83-90. PubMed ID: 15581403
[TBL] [Abstract][Full Text] [Related]
8. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation.
Gill JS; Jamwal S; Kumar P; Deshmukh R
Pharmacol Rep; 2017 Apr; 69(2):306-313. PubMed ID: 28178592
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?
Scheuing L; Chiu CT; Liao HM; Linares GR; Chuang DM
Int J Biol Sci; 2014; 10(9):1024-38. PubMed ID: 25285035
[TBL] [Abstract][Full Text] [Related]
10. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.
Linares GR; Chiu CT; Scheuing L; Leng Y; Liao HM; Maric D; Chuang DM
Exp Neurol; 2016 Jul; 281():81-92. PubMed ID: 27085395
[TBL] [Abstract][Full Text] [Related]
11. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide mechanism in the protective effect of antidepressants against 3-nitropropionic acid-induced cognitive deficit, glutathione and mitochondrial alterations in animal model of Huntington's disease.
Kumar P; Kalonia H; Kumar A
Behav Pharmacol; 2010 May; 21(3):217-30. PubMed ID: 20480544
[TBL] [Abstract][Full Text] [Related]
13. Antidepressants for neuroprotection in Huntington's disease: A review.
Jamwal S; Kumar P
Eur J Pharmacol; 2015 Dec; 769():33-42. PubMed ID: 26511378
[TBL] [Abstract][Full Text] [Related]
14. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
Thomas EA; Coppola G; Desplats PA; Tang B; Soragni E; Burnett R; Gao F; Fitzgerald KM; Borok JF; Herman D; Geschwind DH; Gottesfeld JM
Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15564-9. PubMed ID: 18829438
[TBL] [Abstract][Full Text] [Related]
15. Novel protective mechanisms of antidepressants against 3-nitropropionic acid induced Huntington's-like symptoms: a comparative study.
Kumar P; Kalonia H; Kumar A
J Psychopharmacol; 2011 Oct; 25(10):1399-411. PubMed ID: 20305041
[TBL] [Abstract][Full Text] [Related]
16. Potential drugs and methods for preventing or delaying the progression of Huntington's disease.
Sari Y
Recent Pat CNS Drug Discov; 2011 May; 6(2):80-90. PubMed ID: 21585328
[TBL] [Abstract][Full Text] [Related]
17. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.
Lauterbach EC; Victoroff J; Coburn KL; Shillcutt SD; Doonan SM; Mendez MF
J Neuropsychiatry Clin Neurosci; 2010; 22(1):8-18. PubMed ID: 20160205
[TBL] [Abstract][Full Text] [Related]
18. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
[TBL] [Abstract][Full Text] [Related]
19. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.
Brito V; Puigdellívol M; Giralt A; del Toro D; Alberch J; Ginés S
Cell Death Dis; 2013 Apr; 4(4):e595. PubMed ID: 23598407
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
